{
    "clinical_study": {
        "@rank": "137748", 
        "arm_group": {
            "arm_group_label": "AdimFlu-S", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the antibody response to each of the three\n      influenza vaccine strains included in the licensed seasonal flu vaccine, as measured by\n      hemagglutination inhibition (HAI) at three weeks post immunization in non-elderly and\n      elderly subjects in compliance with the requirements of the current European Union (EU)\n      recommendations for the evaluation of the immunogenicity for a new formulation of a licensed\n      flu vaccine (CPMP/BWP/214/96)."
        }, 
        "brief_title": "Immunogenicity and Safety of a Trivalent Inactivated Influenza Vaccine, Formulation 2012-2013, in Non-Elderly Adult and Elderly Subjects", 
        "completion_date": {
            "#text": "September 2012", 
            "@type": "Actual"
        }, 
        "condition": "Influenza", 
        "condition_browse": {
            "mesh_term": "Influenza, Human"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Males or non-pregnant females and aged \u2265 18 years;\n\n          -  Willing and able to adhere to visit schedules and all study requirements;\n\n          -  Subjects read and signed the study-specific informed consent.\n\n        Exclusion Criteria:\n\n        -"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "130", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "December 17, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01752881", 
            "org_study_id": "FLU12T13A"
        }, 
        "intervention": [
            {
                "arm_group_label": "AdimFlu-S", 
                "description": "AdimFlu-S, Inactivated Influenza Vaccine Trivalent Types A and B (Split) Formulation 2012-2013\nDosage:  0.5mL/per syringe\nAdministration route: Intramuscular Injection, once", 
                "intervention_name": "Influenza vaccine (split virion, inactivated)", 
                "intervention_type": "Biological", 
                "other_name": "AdimFlu-S Influenza Vaccine"
            }, 
            {
                "arm_group_label": "AdimFlu-S", 
                "intervention_name": "AdimFlu-S", 
                "intervention_type": "Biological"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Influenza", 
            "Vaccine", 
            "Immunogenicity"
        ], 
        "lastchanged_date": "December 17, 2012", 
        "location": {
            "facility": {
                "address": {
                    "city": "Tainan", 
                    "country": "Taiwan"
                }, 
                "name": "National Cheng Kung University Hospital"
            }
        }, 
        "location_countries": {
            "country": "Taiwan"
        }, 
        "number_of_arms": "1", 
        "official_title": "Immunogenicity and Safety of a Trivalent Inactivated Influenza Vaccine, Formulation 2012-2013, in Non-Elderly Adult and Elderly Subjects", 
        "overall_official": {
            "affiliation": "National Cheng-Kung University Hospital", 
            "last_name": "Chih-Jen Chang, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Taiwan : Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "August 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "description": "Seroprotection rate is defined as the proportion of subjects with HAI titer \u2265 1:40.", 
                "measure": "Immunogenicity endpoint: Seroprotection rate", 
                "safety_issue": "No", 
                "time_frame": "At 3 weeks after vaccination"
            }, 
            {
                "description": "The seroconversion is defined as the HAI titer of the post-vaccination serum is at least 1:40 for those who had a negative pre-vaccination HAI serum titer or a four-fold or greater increase in HAI titers in subjects who had a positive pre-vaccination HAI serum titer. The seropositive is defined as the HAI titer \u2265 1:10, and the seronegative is defined as HAI titer < 1:10.", 
                "measure": "Immunogenicity endpoint: Seroconversion rate", 
                "safety_issue": "No", 
                "time_frame": "At 3 weeks after vaccination"
            }, 
            {
                "measure": "Immunogenicity endpoint: Geometric mean folds increase in HAI titer", 
                "safety_issue": "No", 
                "time_frame": "At 3 weeks after vaccination"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01752881"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Reactogenicity events are pre-specified adverse events systematically recorded for 7 days after vaccination. The selection of the events to be collected systematically is based on events expected to occur with wild-type influenza infection including fever (\u226538\u00b0C), runny nose or nasal congestion, cough, sore throat, headache, muscle aches, vomiting, nausea and malaise. Furthermore, the local (injection site) reactions will also be evaluated that include soreness/pain, swelling, redness, ecchymosis and limitation of arm motion.", 
                "measure": "Safety: Reactogenicity events", 
                "safety_issue": "Yes", 
                "time_frame": "7 days after vaccination"
            }, 
            {
                "measure": "Safety: Serious and non-serious adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "Through day 21 post vaccination"
            }
        ], 
        "source": "Adimmune Corporation", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Adimmune Corporation", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2012", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "December 2012"
    }
}